Ending Drug Company Price Discrimination in the U.S.

By K. C. Moss. Stanford University. 

To make affordable health coverage a reality for more Americans, the government has a responsibility to ensure that drug costs reflect a competitive market. Currently, many drug companies price discriminate, charging higher prices in the U.S. for the same drug sold for less in other countries. A fair and effective change in health coverage would be to forbid this price discrimination, which would ultimately increase access to affordable, comprehensive healthcare. In evaluating the positive effects of this change, one must look to its impact on the three areas of greatest concern in the healthcare industry.

Read the full paper here.